Pfizer revenue for the fourth quarter was $23.8 billion, up 105% from the same quarter in 2020.
Pfizer now expects approximately $55 billion in combined revenues for its Covid-19 vaccine and antiviral in 2022, and what would be a record high overall revenue of between $98 billion and $102 billion.
Pfizer’s 2022 revenue guidance range was slightly below the FactSet consensus estimate of $103.2 billion. Pfizer expects $32 billion in revenue from Comirnaty, below the FactSet consensus estimate of $34.8 billion, and $22 billion in revenue for Paxlovid, in line with the $22 billion FactSet consensus estimate.
Sales of the company’s blockbuster pneumococcal vaccines, Prevnar 13 and Prevnar 20, were down 25% to $1.3 billion globally in the fourth quarter, a drop the company attributed to unfavorable timing of government purchases in the U.S. The company’s chief scientific officer, Mikael Dolsten, said that Pfizer is planning to start human trials for an improved version of its antiviral in the second half of 2022.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Covid vaccine gives Pfizer sales and profits a big boostPfizer's sales in the fourth quarter more than doubled, thanks to strong demand for its Covid-19 vaccine. But that wasn't good enough to satisfy investors.
Lire la suite »
Pfizer Forecasts Record Vaccine Revenue for 2022 as Billions Remain Unprotected'It's nothing short of pandemic profiteering for Pfizer to make a killing while its vaccines have been withheld from so many.'
Lire la suite »
Peloton stock continues rally as company replaces John Foley as CEOPeloton Interactive Inc.'s newly announced chief executive will face a lowered bar as the maker of exercise equipment once again cut its full-year forecast...
Lire la suite »
Stock futures inch higher after S&P, Nasdaq fall to start the weekU.S. stock index futures were flat during overnight trading Monday.
Lire la suite »
Rep. Jamie Raskin slapped with ethics complaint over failure to report wife's huge stock payoutDemocratic Rep. Jamie Raskin was hit Monday with an ethics complaint over his failure to properly disclose stock shares that his wife, Sarah Bloom Raskin, received for her work at a Colorado-based financial technology company.
Lire la suite »
What We Don’t Know About the Stock MarketExtraordinary moves in Big Tech stocks in response to small changes in their earnings show what a wacky market we’re in. In short, nobody knows anything, writes jmackin2
Lire la suite »